New York, May 30, 2013 -- Moody's Investors Service commented that the planned upsized term loan and revolving credit agreement of Jazz Pharmaceuticals, Inc. is credit negative because of added financial leverage. However, Jazz's credit metrics will remain healthy and within Moody's expectations for the Ba3 rating. There are no changes to Jazz's ratings including the Ba3 Corporate Family Rating, the B1-PD Probability of Default Rating, the Ba3 senior secured rating or the SGL-1 Speculative Grade Liquidity Rating. The rating outlook is stable.
Vollständigen Artikel bei Moodys lesen
Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.